ArticleACS medicinal chemistry letters2019

Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.

Angela De Simone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.